News

Scripps Research announces its 2024 recipients of Collaborative Innovation Fund grants.

Insights could advance new drugs to treat the progressive, fatal disease known as transthyretin amyloidosis.

Calibr-Skaggs’ long-acting injectable (LAI) platform transforms oral malaria treatment atovaquone, aiming for protection from malaria for three months.

Scripps Research scientists discovered that repetitive HIV vaccinations can lead the body to produce antibodies targeting the immune complexes already bound to the virus—knowledge that could lead to better vaccines.

New findings reveal a technique to transform essential chemical building blocks for drug discovery and beyond—representing the “final step” in applying this method to all key classes of organic molecules.

By using computer modeling to predict chemical reactions, Scripps Research scientists were able to synthesize 25 variations of a plant compound that could treat brain diseases.

A new study uncovers how DNA, magnesium and polyphosphate form a balance that’s just right—which could lead to innovations in medicine and biotechnology.

Scripps Research scientists reveal microgravity’s effects on brain cells.

The National Institutes for Health’s (NIH) HEAL Initiative has awarded Alejandra Mendoza, PhD, assistant professor of Immunology and Microbiology, more than $1.6 million as part of a DP2 grant designed to support early-stage investigators with highly innovative and impactful research.

A new, more sustainable AI model recognizes visual scenes by mirroring brain processes, opening doors for applications in medical diagnostics, drug discovery and beyond.

Scripps Research scientists and collaborators use an innovative set of machine-learning models to discover a record-breaking material for film capacitors, key components in many energy technologies.

New findings underscore the importance of ongoing surveillance for H5N1 mutations that pose risks to public health.

Funding from ARPA-H will be used to develop a vaccine for alphaviruses in preparation of major outbreaks in the U.S.

Technologies developed by both teams will map the human eye-brain connectome, extend the lifespan of the revived human eye, and help regenerate and monitor the optic nerve after a whole eye transplant.

Featured scientists represent a wide range of fields including chemistry, microbiology, immunology, neuroscience and more

Scripps Research scientists improved existing vaccines by analyzing the molecular structure and stability of viral proteins.

Scripps Research has added Benjamin Cravatt, PhD, professor of Chemistry and the Norton B. Gilula Chair in Biology and Chemistry at Scripps Research, and Lou Lange, MD, PhD, physician-scientist and general partner with Asset Management Ventures, to its Board of Directors.

By examining RNA in hundreds of thousands of individual brain cells, Scripps Research scientists further support that alcohol use disorder could accelerate Alzheimer’s disease progression, paving the way for future targeted treatments.

CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue. 

Scientists at Scripps Research and its drug discovery arm, Calibr-Skaggs, develop first-in-class small molecules to repair damaged tissues of the heart, lungs, joints, and more.  

By creating personalized brain “organoids” in the lab, Scripps Research scientists showed how microRNAs impact brain development, and demonstrate how one drug can reverse critical cellular signs of autism.

Scripps Research scientists show that alcohol withdrawal causes long-lasting sensitivity to mechanical stimuli in heavy drinkers, and identify a drug target that could help.

Scientists uncover how small molecules interact with a cancer-related protein called FOXA1 and identify a crucial binding site on its surface.

The two distinct awards will support collaborative research projects into pollution’s impact on autism as well as risk genes in psychiatric disorders.